Bristol Myers Squibb BMY
NYSE BMY
$67.36 +1.89 (+2.89%)
As of: Aug 21, 2026 · 12:54 PM EDT

Bristol Myers Squibb Co (BMY) EBT (2009 - 2026)

Bristol Myers Squibb (BMY) posted quarterly EBT of $4.1 billion for Q2 2026, up 130.46% year-over-year from $1.8 billion in Q2 2025, and up 26.11% quarter-over-quarter from $3.2 billion in Q1 2026.

Bristol Myers Squibb Co (BMY) EBT (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (BMY) has reported EBT for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

  • In Q2 2026, EBT rose 130.46% year-over-year to $4.1 billion; the TTM figure through Jun 2026 stood at $11.9 billion (up 80.59% YoY), while the FY2025 annual figure was $9.3 billion, up 211.33% from the prior year.
  • EBT improved to $4.1 billion in Q2 2026 per BMY's latest filing, from $3.2 billion in the prior quarter.
  • Across five years, EBT topped out at $4.1 billion in Q2 2026 and bottomed at -$11.5 billion in Q1 2024.
  • Historically, EBT has averaged $1.4 billion across 5 years, with a median of $1.9 billion in 2022.
  • Annual changes were most pronounced in 2024 — EBT plunged 515.74% — and 2025, when it surged 740.0%.
  • Bristol Myers Squibb's EBT stood at $1.9 billion in 2022, then decreased by 9.95% to $1.7 billion in 2023, then slumped by 89.55% to $175.0 million in 2024, then soared by 740.0% to $1.5 billion in 2025, then soared by 177.96% to $4.1 billion in 2026.
  • Business Quant data shows BMY's EBT at $4.1 billion in Q2 2026, $3.2 billion in Q1 2026, and $1.5 billion in Q4 2025.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2026 4.09 Bn
Mar 31, 2026 3.24 Bn
Dec 31, 2025 1.47 Bn
Sep 30, 2025 3.11 Bn
Jun 30, 2025 1.77 Bn
Mar 31, 2025 2.97 Bn
Dec 31, 2024 175.00 Mn
Sep 30, 2024 1.68 Bn
Jun 30, 2024 1.29 Bn
Mar 31, 2024 -11.52 Bn
Dec 31, 2023 1.67 Bn
Sep 30, 2023 2.14 Bn
Jun 30, 2023 1.86 Bn
Mar 31, 2023 2.77 Bn
Dec 31, 2022 1.86 Bn
Sep 30, 2022 2.21 Bn
Jun 30, 2022 1.96 Bn
Mar 31, 2022 1.69 Bn
Dec 31, 2021 1.86 Bn
Sep 30, 2021 2.16 Bn